Home

DAVID ALTSHULER

CIK 1550395 · EVP, Chief Scientific Officer · last filed 2026-01-26

DAVID ALTSHULER is an EVP, Chief Scientific Officer who has filed 122 SEC Form 4 insider transactions across 1 company since 2012. The most recent filing, for VRTX, was dated Jan 26, 2026. Across all open-market trades the lifetime net is −$94.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.1M across reported positions. 124 SEC filings were submitted jointly with VERTEX PHARMACEUTICALS INC / MA.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$16.06M

Companies

1

Total Filings

122

Lifetime Open-Market Net

-$94.49M

Filer Profile

Reported Address
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Related Filers
VERTEX PHARMACEUTICALS INC / MA — 124 joint filings, latest 2026-01-26
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VRTX EVP, Chief Scientific Officer 31,149 $515.44 $16.06M -$94.49M 107 2026-01-26

Recent Filings

122 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-26 VRTX Grant (A) +11,194 $0 EDGAR
2025-05-19 VRTX Sell (S) −52 -$22.1K EDGAR
2025-05-15 VRTX Notice (144) −52 -$22.1K EDGAR
2025-03-17 VRTX Sell (S) −3,231 -$1.65M EDGAR
2025-03-13 VRTX Notice (144) −3,231 -$1.65M EDGAR
2025-03-12 VRTX Sell (S) −3,231 -$1.62M EDGAR
2025-03-10 VRTX Notice (144) −3,231 -$1.62M EDGAR
2025-03-05 VRTX Sell (S) −3,231 -$1.58M EDGAR
2025-03-03 VRTX Notice (144) −3,231 -$1.58M EDGAR
2025-02-28 VRTX Mixed −7,226 -$3.47M EDGAR
Showing 1–10 of 122
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.